Journal of Cardiac Failure
Volume 13, Issue 5 , Pages 380-388 , June 2007

Increased Brain Natriuretic Peptide Secretion is a Marker of Disease Progression in Nonobstructive Hypertrophic Cardiomyopathy

  • Maurizio Pieroni, MD, PhD

      Affiliations

    • From the Cardiology Department, Catholic University, Rome, Italy
    • Corresponding Author InformationReprint requests: Maurizio Pieroni Cardiology Department, Catholic University, Largo A. Gemelli 8, 00168 Rome, Italy.
    • ,
  • Fulvio Bellocci, MD

      Affiliations

    • From the Cardiology Department, Catholic University, Rome, Italy
    • ,
  • Tommaso Sanna, MD

      Affiliations

    • From the Cardiology Department, Catholic University, Rome, Italy
    • ,
  • Romina Verardo, PhD

      Affiliations

    • From the Cardiology Department, Catholic University, Rome, Italy
    • ,
  • Carolina Ierardi, MD

      Affiliations

    • From the Cardiology Department, Catholic University, Rome, Italy
    • ,
  • Attilio Maseri, MD

      Affiliations

    • Cardio-Thoracic and Vascular Department, San Raffaele Hospital, Milan, Italy
    • ,
  • Andrea Frustaci, MD

      Affiliations

    • Heart and Great Vessels Department “Attilio Reale,” La Sapienza University, Rome, Italy
    • ,
  • Filippo Crea, MD

      Affiliations

    • From the Cardiology Department, Catholic University, Rome, Italy

Received 4 May 2006 ,Revised 29 January 2007 ,Accepted 30 January 2007.

References 

  1. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321–327
  2. Nakagawa O, Ogawa Y, Itoh H, Suga S, Komatsu Y, Kishimoto I, et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an “emergency” cardiac hormone against ventricular overload. J Clin Invest. 1995;3:1280–1287
  3. Yoshimura M, Yasue H, Morita E, Sakaino N, Jougasaki M, Kurose M, et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation. 1991;84:1581–10
  4. Mizuno Y, Yoshimura M, Harada E, Nakayama M, Sakamoto T, Shimasaki Y, et al. Plasma levels of A- and B-type natriuretic peptides in patients with hypertrophic cardiomyopathy or idiopathic dilated cardiomyopathy. Am J Cardiol. 2000;86:1036–1040
  5. Takemura G, Takatsu Y, Doyama K, Itoh H, Saito Y, Koshiji M, et al. Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis. J Am Coll Cardiol. 1998;31:754–765
  6. Hasegawa K, Fujiwara H, Doyama K, Miyamae M, Fujiwara T, Suga S, et al. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation. 1993;88:372–380
  7. Nishigaki K, Tomita M, Kagawa K, Noda T, Minatoguchi S, Oda H, et al. Marked expression of plasma brain natriuretic peptide is a special feature of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 1996;28:1234–1242
  8. Briguori C, Betocchi S, Manganelli F, Gigante B, Losi MA, Ciampi Q, et al. Determinants and clinical significance of natriuretic peptides in hypertrophic cardiomyopathy. Eur Heart J. 2001;22:1328–1336
  9. Mukoyama M, Nakao K, Saito Y, Ogawa Y, Hosoda K, Suga S, et al. Increased human brain natriuretic peptide in congestive heart failure. N Engl J Med. 1990;323:757–758
  10. Maron BJ, Tholakanahalli VN, Zenovich AG, Casey SA, Duprez D, Aeppli DM, et al. Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation. 2004;109:984–989
  11. Frenneaux MP, Porter A, Caforio AL, Odawara H, Counihan PJ, McKenna WJ. Determinants of exercise capacity in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1992;19:1521–1526
  12. Sharma S, Elliott P, Whyte G, Jones S, Mahon N, Whipp B, et al. Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy. Am J Cardiol. 2000;86:162–168
  13. Maron BJ, Spirito P. Implications of left ventricular remodeling in hypertrophic cardiomyopathy. Am J Cardiol. 1998;81:1339–1344
  14. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet. 2004;363:1881–1891
  15. Thaman R, Gimeno JR, Reith S, Esteban MT, Limongelli G, Murphy RT, et al. Progressive left ventricular remodeling in patients with hypertrophic cardiomyopathy and severe left ventricular hypertrophy. J Am Coll Cardiol. 2004;44:398–405
  16. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287:1308–1320
  17. Nakae I, Mitsunami K, Omura T, Yabe T, Tsutamoto T, Matsuo S, et al. Proton magnetic resonance spectroscopy can detect creatine depletion associated with the progression of heart failure in cardiomyopathy. J Am Coll Cardiol. 2003;42:1587–1593
  18. Pieroni M, Chimenti C, Ricci R, Russo MA, Sale P, Maseri A, et al. Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation. 2003;107:1978–1984
  19. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358–367
  20. Arad M, Seidman JG, Seidman CE. Phenotypic diversity in hypertrophic cardiomyopathy. Hum Mol Genet. 2002;11:2499–2506
  21. Chien KR. Genotype, phenotype: upstairs, downstairs in the family of cardiomyopathies. J Clin Invest. 2003;111:175–178
  22. Harris KM, Spirito P, Maron MS, Zenovich AG, Formisano F, Lesser , et al. Prevalence, clinical profile and significance of left ventricular remodeling in end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006;114:216–225
  23. Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med. 2003;349:1027–1035
  24. Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart. 2000;84:476–482
  25. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol. 2003;41:1561–1567
  26. Mariano-Goulart D, Eberle MC, Boudousq V, Hejazi-Moughari A, Piot C, Caderas de Kerleau C, et al. Major increase in brain natriuretic peptide indicates right ventricular systolic dysfunction in patients with heart failure. Eur J Heart Fail. 2003;5:481–488
  27. Kapoun AM, Liang F, O'Young G, Damm DL, Quon D, White RT, et al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res. 2004;94:453–461
  28. Langenickel T, Pagel I, Hohnel K, Dietz R, Willenbrock R. Differential regulation of cardiac ANP and BNP mRNA in different stages of experimental heart failure. Am J Physiol Heart Circ Physiol. 2000;278:H1500–H1506
  29. Nagaya N, Nishikimi T, Okano Y, Uematsu M, Satoh T, Kyotani S, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol. 1998;31:202–208
  30. Tulevski II, Groenink M, van Der Wall EE, van Veldhuisen DJ, Boomsma F, Stoker J, et al. Increased brain and atrial natriuretic peptides in patients with chronic right ventricular pressure overload: correlation between plasma neurohormones and right ventricular dysfunction. Heart. 2001;86:27–30
  31. Adachi S, Ito H, Ohta Y, Tanaka M, Ishiyama S, Nagata M, et al. Distribution of mRNAs for natriuretic peptides in RV hypertrophy after pulmonary arterial banding. Am J Physiol. 1995;268:H162–H169

PII: S1071-9164(07)00012-7

doi: 10.1016/j.cardfail.2007.01.011

Journal of Cardiac Failure
Volume 13, Issue 5 , Pages 380-388 , June 2007

Article Tools

* Image Usage & Resolution